{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T08:47:22Z","timestamp":1751359642549,"version":"3.37.3"},"reference-count":45,"publisher":"Bentham Science Publishers Ltd.","issue":"2","funder":[{"DOI":"10.13039\/501100006014","name":"College of Medicine and Health Sciences, United Arab Emirates University","doi-asserted-by":"publisher","award":["CMHS-NP-15-01","NP-15-0"],"award-info":[{"award-number":["CMHS-NP-15-01","NP-15-0"]}],"id":[{"id":"10.13039\/501100006014","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CVP"],"published-print":{"date-parts":[[2020,1,27]]},"abstract":"<jats:sec>\n<jats:title>Aim:<\/jats:title>\n<jats:p>We investigated the incidence of adverse drug reactions (ADRs) in patients treated with\nstatins for cardiovascular (CV) risk among the United Arab Emirates (UAE) population.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>This is a retrospective cohort study conducted among statin users attending 2 tertiary care\ncentres: Al Ain and Tawam hospitals in Al Ain city, UAE. We retrieved the clinical profile of all the\npatients taking statins from January 2011 to January 2015 using our electronic database (Cerner\u00ae).<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>Among 556 patients (418 men; 138 women) taking statins, 237 ADRs were reported (186 men;\n51 women). The incidence of ADRs was 40.7%, and was more frequent among patients at \u201chigh CV\ndisease (CVD) risk\u201d and \u201cmoderate CVD risk\u201d than other risk categories. High CVD risk (odds ratio,\n1.67; 95% confidence interval [CI], 1.19-2.34), vitamin D deficiency 1.45 (95% CI, 0.89-2.38), type 2\ndiabetes 1.22 (95% CI, 0.84-1.77) and hypertension 1.13 (95% CI, 0.70-1.83) are some of the factors\nthat were associated with statin ADRs.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>The incidence of ADRs among statin users was 42.6%, and frequent ADRs (49%) were\nnoted in patients with high CVD risk. Early identification of these ADRs should improve patient adherence\nto life-saving statin treatment.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1570161117666190408164908","type":"journal-article","created":{"date-parts":[[2019,4,9]],"date-time":"2019-04-09T07:44:27Z","timestamp":1554795867000},"page":"193-199","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The Incidence of Adverse Drug Reactions in Patients Treated with Statins in the Emirates: A Retrospective Cohort Study"],"prefix":"10.2174","volume":"18","author":[{"given":"Abdulla","family":"Shehab","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, United Arab Emirates University, College of Medicine and Health Sciences, Al Ain, United Arab Emirates"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akshaya S.","family":"Bhagavathula","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, United Arab Emirates University, College of Medicine and Health Sciences, Al Ain, United Arab Emirates"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asim A.","family":"Elnour","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, Pharmacy College, Gulf Medical University, Ajman, United Arab Emirates"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khalid","family":"Al-Rasadi","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, Sultan Qaboos University Hospital, Muscat, Oman"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saif","family":"Al-Shamsi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, United Arab Emirates University, College of Medicine and Health Sciences, Al Ain, United Arab Emirates"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1001\/jama.285.19.2486","volume":"285","year":"2001","unstructured":"Executive summary of The third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults2001,285,2486-2497","journal-title":"JAMA"},{"key":"ref=2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.phrs.2014.03.002","volume":"88","author":"Sirtori C.R.","year":"2014","unstructured":"Sirtori C.R.; The pharmacology of statins. Pharmacol Res 2014,88,3-11","journal-title":"Pharmacol Res"},{"key":"ref=3","first-page":"465","volume":"1","author":"Smith S.","year":"2016","unstructured":"Smith S.; The 2013 ACC\/AHA guidelines on treatment of blood cholesterol to improve cardiovascular outcomes: Implications for statin use and dose vs. target. Cardiovasc Innov Appl 2016,1,465-467","journal-title":"Cardiovasc Innov Appl"},{"key":"ref=4","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1161\/CIRCRESAHA.118.313245","volume":"124","author":"Hadjiphilippou S.","year":"2019","unstructured":"Hadjiphilippou S.; Ray K.K.; Choesterol-lowering agents. Circ Res 2019,124,354-363","journal-title":"Circ Res"},{"key":"ref=5","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1161\/CIRCULATIONAHA.106.624890","volume":"114","author":"Kashani A.","year":"2006","unstructured":"Kashani A.; Phillips C.O.; Foody J.M.; Risks associated with statin therapy. Circulation 2006,114,2788-2797","journal-title":"Circulation"},{"key":"ref=6","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1016\/S0140-6736(16)31357-5","volume":"388","author":"Collins R.","year":"2016","unstructured":"Collins R.; Reith C.; Emberson J.; Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet 2016,388,2532-2561","journal-title":"Lancet"},{"key":"ref=7","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1093\/eurheartj\/ehv043","volume":"36","author":"Stroes E.S.","year":"2015","unstructured":"Stroes E.S.; Thompson P.D.; Corsini A.; Statin-associated muscle symptoms: Impact on statin therapy-European Atherosclerosis Society consensus panel statement on assessment, aetiology and management. Eur Heart J 2015,36,1012-1022","journal-title":"Eur Heart J"},{"key":"ref=8","doi-asserted-by":"crossref","first-page":"858","DOI":"10.7326\/0003-4819-150-12-200906160-00009","volume":"150","author":"Joy T.R.","year":"2009","unstructured":"Joy T.R.; Hegele R.A.; Narrative review: Statin-related myopathy. Ann Intern Med 2009,150,858-868","journal-title":"Ann Intern Med"},{"key":"ref=9","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.amjcard.2006.02.030","volume":"97","author":"McKenney J.M.","year":"2006","unstructured":"McKenney J.M.; Davidson M.H.; Jacobson T.A.; Final conclusion and recommendations of the National lipid association statin safety assessment task force. Am J Cardiol 2006,97,89-94","journal-title":"Am J Cardiol"},{"key":"ref=10","doi-asserted-by":"crossref","first-page":"636","DOI":"10.4103\/2230-8210.113754","volume":"17","author":"Maji D.","year":"2013","unstructured":"Maji D.; Shaikh S.; Solanki D.; Safety of statins. Indian J Endocrinol Metab 2013,17,636","journal-title":"Indian J Endocrinol Metab"},{"key":"ref=11","doi-asserted-by":"crossref","first-page":"52C","DOI":"10.1016\/j.amjcard.2005.12.010","volume":"97","author":"Law M.","year":"2006","unstructured":"Law M.; Rudnicka A.R.; Statin safety: a systematic review. Am J Cardiol 2006,97(Suppl.),52C-60C","journal-title":"Am J Cardiol"},{"key":"ref=12","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1016\/j.clinthera.2008.11.012","volume":"30","author":"Chodick G.","year":"2008","unstructured":"Chodick G.; Shalev V.; Gerber Y.; Long-term persistence with statin treatment in a not-for-profit health maintenance organization: a population-based retrospective cohort study in Israel. Clin Ther 2008,30,2167-2179","journal-title":"Clin Ther"},{"key":"ref=13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5114\/aoms.2015.49807","volume":"11","author":"Banach M.","year":"2015","unstructured":"Banach M.; Rizzo M.; Toth P.P.; Statin intolerance - an attempt at a unified definition. Position paper from an International Lipid Expert Panel. Arch Med Sci 2015,11,1-23","journal-title":"Arch Med Sci"},{"key":"ref=14","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0140-6736(09)61965-6","volume":"375","author":"Sattar N.","year":"2010","unstructured":"Sattar N.; Preiss D.; Murray H.M.; Statins and risk of incident diabetes: a collaborative meta-analysis of randomized statin trials. Lancet 2010,375,735-742","journal-title":"Lancet"},{"key":"ref=15","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1093\/qjmed\/hcq165","volume":"104","author":"Mills E.J.","year":"2011","unstructured":"Mills E.J.; Wu P.; Chong G.; Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170,255 patients from 76 randomized trials. QJM 2011,104,109-124","journal-title":"QJM"},{"key":"ref=16","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2017-000438","volume":"5","author":"Crandall J.P.","year":"2017","unstructured":"Crandall J.P.; Mather K.; Rajpathak S.N.; Statin use and risk of developing diabetes: results from the Diabetes Prevention Program. BMJ Open Diabetes Res Care 2017,5","journal-title":"BMJ Open Diabetes Res Care"},{"key":"ref=17","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1161\/ATV.0000000000000073","volume":"39","author":"Newman C.B.","year":"2019","unstructured":"Newman C.B.; Preiss D.; Tobert J.A.; Statin safety and associated adverse events: a scientific statement from the American Heart Association. Arterioscler Thromb Vasc Biol 2019,39,e38-e81","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref=18","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.1016\/j.jacc.2013.11.005","volume":"63","author":"Goff D.C.","year":"2014","unstructured":"Goff D.C.; Lloyd-Jones D.M.; Bennett G.; 2013 ACC\/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014,63(25 Part B),2935-2959","journal-title":"J Am Coll Cardiol"},{"key":"ref=19","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1093\/eurheartj\/ehr158","volume":"32","author":"Reiner Z.","year":"2011","unstructured":"Reiner Z.; Catapano A.L.; De Backer G.; ESC\/EAS guidelines for the management of dyslipidemias: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011,32,1769-1818","journal-title":"Eur Heart J"},{"key":"ref=20","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/S0735-1097(02)02030-2","volume":"40","author":"Pasternak R.C.","year":"2002","unstructured":"Pasternak R.C.; Smith S.C.; Bairey-Merz C.N.; ACC\/AHA\/NHLBI clinical advisory on the use and safety of statins. J Am Coll Cardiol 2002,40,567-572","journal-title":"J Am Coll Cardiol"},{"key":"ref=21","unstructured":"National Kidney Foundation. K\/DOQI clinical practice guidelines for chronic kidney disease: evaluation classification, and stratification. 2000. Available at\n                     ext-link-type=\"uri\" xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/www.kidney.org\/professionals\/kdoqi\/guidelines_ckd\/toc.htm\">www.kidney.org\/professionals\/kdoqi\/guidelines_ckd\/toc.htm Accessed May 23,2015."},{"key":"ref=22","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1016\/j.jacc.2013.11.002","volume":"63","author":"Stone N.J.","year":"2014","unstructured":"Stone N.J.; Robinson J.G.; Lichtenstein A.H.; 2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014,63(25 Part B),2889-2934","journal-title":"J Am Coll Cardiol"},{"key":"ref=23","unstructured":"US Food and Drug Administration. FDA drug safety communication: Important safety label changes to cholesterol-lowering statin drugs. US Food and Drug Administration Web site. Available at:\n                     ext-link-type=\"uri\" xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/www.fda.gov\/drugs\/drugsafety\/ucm293101.htm\">http: \/\/www.fda.gov\/drugs\/drugsafety\/ucm293101.htm Accessed June 23,2015."},{"key":"ref=24","unstructured":"US Food and Drug Administration. FDA drug safety communication: Ongoing safety review of high-dose Zocor (simvastatin) and increased risk of muscle injury. US Food and Drug Administration Web site. Available at:\n                     ext-link-type=\"uri\" xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/ucm204882.htm.Updated\">http:\/\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/ucm204882.htm.Updated\n                    February 15, 2012. Accessed November 10, 2015."},{"key":"ref=25","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1002\/phar.1272","volume":"33","author":"Mansi I.","year":"2013","unstructured":"Mansi I.; Frei C.R.; Pugh M.J.; Psychologic Disorders and Statin Use: A Propensity Score\u2010Matched Analysis. Pharmacotherapy 2013,33,615-626","journal-title":"Pharmacotherapy"},{"key":"ref=26","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1345\/aph.1Q620","volume":"46","author":"Rojas-Fernandez C.H.","year":"2012","unstructured":"Rojas-Fernandez C.H.; Cameron J.C.; Is statin-associated cognitive impairment clinically relevant? A narrative review and clinical recommendations. Ann Pharmacother 2012,46,549-557","journal-title":"Ann Pharmacother"},{"key":"ref=27","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1001\/jama.283.21.2829","volume":"283","author":"McAlister F.A.","year":"2000","unstructured":"McAlister F.A.; Straus S.E.; Guyatt G.H.; Haynes R.B.; Users\u2019 guides to the medical literature, XX: integrating research evidence with the care of the individual patient. JAMA Evidence-Based Medicine Working Group2000,283,2829-2836","journal-title":"JAMA"},{"key":"ref=28","first-page":"FC01","volume":"11","author":"Indumathi C.","year":"2017","unstructured":"Indumathi C.; Anusha N.; Vinod K.V.; Atorvastatin Induced Adverse Drug Reactions among South Indian Tamils. J Clin Diagn Res 2017,11,FC01","journal-title":"J Clin Diagn Res"},{"key":"ref=29","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s10557-005-5686-z","volume":"19","author":"Bruckert E.","year":"2005","unstructured":"Bruckert E.; Hayem G.; Dejager S.; Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients\u2013the PRIMO study. Cardiovasc Drugs Ther 2005,19,403-414","journal-title":"Cardiovasc Drugs Ther"},{"key":"ref=30","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ahj.2014.03.019","volume":"168","author":"Ganga H.V.","year":"2014","unstructured":"Ganga H.V.; Slim H.B.; Thompson P.D.; A systematic review of statin-induced muscle problems in clinical trials. Am Heart J 2014,168,6-15","journal-title":"Am Heart J"},{"key":"ref=31","first-page":"275","volume":"53","author":"Siegel A.J.","year":"1980","unstructured":"Siegel A.J.; Silverman L.M.; Lopez R.E.; Creatine kinase elevations in marathon runners: relationship to training and competition. Yale J Biol Med 1980,53,275-279","journal-title":"Yale J Biol Med"},{"key":"ref=32","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1093\/qjmed\/hch035","volume":"97","author":"Golomb B.A.","year":"2004","unstructured":"Golomb B.A.; Kane T.; Dimsdale J.E.; Severe irritability associated with statin cholesterol-lowering drugs. QJM 2004,97,229-235","journal-title":"QJM"},{"key":"ref=33","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1177\/147323000002800601","volume":"28","author":"Manfredini R.","year":"2000","unstructured":"Manfredini R.; Caracciolo S.; Salmi R.; The association of low serum cholesterol with depression and suicidal behaviors: new hypotheses for the missing link. J Int Med Res 2000,28,247-257","journal-title":"J Int Med Res"},{"key":"ref=34","doi-asserted-by":"crossref","first-page":"195","DOI":"10.2165\/00002018-200730030-00003","volume":"30","author":"Tatley M.","year":"2007","unstructured":"Tatley M.; Savage R.; Psychiatric adverse reactions with statins, fibrates and ezetimibe: implications for the use of lipid-lowering agents. Drug Saf 2007,30,195-201","journal-title":"Drug Saf"},{"key":"ref=35","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s40264-014-0163-x","volume":"37","author":"Takada M.","year":"2014","unstructured":"Takada M.; Fujimoto M.; Yamazaki K.; Association of statin use with sleep disturbances: data mining of a spontaneous reporting database and a prescription database. Drug Saf 2014,37,421-431","journal-title":"Drug Saf"},{"key":"ref=36","first-page":"915","volume":"11","author":"Broncel M.","year":"2015","unstructured":"Broncel M.; Gorzelak-Pabi\u015b P.; Sahebkar A.; Sleep changes following statin therapy: a systematic review and meta-analysis of randomized placebo-controlled polysomnographic trials. Arch Med Sci Lipid and Blood Pressure Meta-analysis Collaboration2015,11,915-926","journal-title":"Arch Med Sci"},{"key":"ref=37","unstructured":"US Food and Drug Administration. The center for health and wellness.\n                     ext-link-type=\"uri\" xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/www.fda.org\/drugs\/drugssafety\/ucm293101.htm\">http: \/\/www.fda.org\/drugs\/drugssafety\/ucm293101.htm Accessed June 22, 2018."},{"key":"ref=38","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1592\/phco.29.7.800","volume":"29","author":"Marcella A.","year":"2009","unstructured":"Marcella A.; Evans B.S.; Beatrice A.; Statin-associated adverse cognitive effects: survey results from 171 patients. Pharmacotherapy 2009,29,800-811","journal-title":"Pharmacotherapy"},{"key":"ref=39","doi-asserted-by":"crossref","first-page":"688","DOI":"10.7326\/0003-4819-159-10-201311190-00007","volume":"159","author":"Richardson K.","year":"2013","unstructured":"Richardson K.; Schoen M.; French B.; Statins and cognitive function. Ann Intern Med 2013,159,688-697","journal-title":"Ann Intern Med"},{"key":"ref=40","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1592\/phco.23.6.726.32184","volume":"23","author":"Etminan M.","year":"2003","unstructured":"Etminan M.; Gill S.; Samii A.; The role of lipid-lowering drugs in cognitive function: a meta-analysis of observational studies. Pharmacotherapy 2003,23,726-730","journal-title":"Pharmacotherapy"},{"key":"ref=41","doi-asserted-by":"crossref","first-page":"416","DOI":"10.2174\/156720508785132316","volume":"5","author":"Sparks D.L.","year":"2008","unstructured":"Sparks D.L.; Kryscio R.J.; Sabbagh M.N.; Reduced risk of the incident AD with elective statin use in a clinical trial cohort. Curr Alzheimer Res 2008,5,416-421","journal-title":"Curr Alzheimer Res"},{"key":"ref=42","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1212\/01.wnl.0000288181.00826.63","volume":"70","author":"Arvanitakis Z.","year":"2008","unstructured":"Arvanitakis Z.; Schneider J.A.; Wilson R.S.; Statins, incident Alzheimer disease, change in cognitive function, and neuropathology. Neurology 2008,70,1795-1802","journal-title":"Neurology"},{"key":"ref=43","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1212\/01.wnl.0000279333.77404.d7","volume":"69","author":"Szwast S.J.","year":"2007","unstructured":"Szwast S.J.; Hendrie H.C.; Lane K.A.; Association of statin use with cognitive decline in elderly African Americans. Neurology 2007,69,1873-1880","journal-title":"Neurology"},{"key":"ref=44","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1592\/phco.23.7.871.32720","volume":"23","author":"Wagstaff L.R.","year":"2003","unstructured":"Wagstaff L.R.; Mitton M.W.; Arvik B.M.; Statin\u2010associated memory loss: analysis of 60 case reports and review of the literature. Pharmacotherapy 2003,23,871-880","journal-title":"Pharmacotherapy"},{"key":"ref=45","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.jacl.2014.03.004","volume":"8","author":"Rosenson R.S.","year":"2014","unstructured":"Rosenson R.S.; Baker S.K.; Jacobson T.A.; An assessment by the statin muscle safety task force: 2014 update. J Clin Lipidol 2014,8,558-571","journal-title":"J Clin Lipidol"}],"container-title":["Current Vascular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/171453","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,21]],"date-time":"2020-02-21T13:58:49Z","timestamp":1582293529000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/171453\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,27]]},"references-count":45,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,1,27]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1570161117666190408164908","relation":{},"ISSN":["1570-1611"],"issn-type":[{"type":"print","value":"1570-1611"}],"subject":[],"published":{"date-parts":[[2020,1,27]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2018-11-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-03-14","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-03-29","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-01-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}